La diagnosi molecolare nelle malattie lisosomiali

Translated title of the contribution: Molecular analysis of lysosomal storage disease

M. Filocamo, M. Stroppiano, S. Regis, R. Mazzotti, F. Corsolini, G. Bonuccelli

Research output: Contribution to journalArticle

Abstract

Lysosomal storage disorders (LSD) represent a group of at least 44 distinct genetic disease, each one resulting from a deficiency of a specific enzyme or from protein that are involved in lysosomal biogenesis. Today, with the advent of the new technologies, capabilities to characterise LSDs biochemically and genetically have increased. Contrary to all expectations, the results of the molecular analysis have not always explained the broad clinical heterogeneity of the distinct defects as well as proved very useful to predict the disease severity. However, the molecular analysis makes the diagnosis of carriers and the prenatal tests more reliable. Furthermore, the expression studies of the mutant proteins have improved the knowledge in pathogenesis of the diseases and, sometimes, have provided useful information for therapy establishment. Considering the vast number of mutations for each defect and the accuracy need for the analyses, the cost-benefit analysis requires a careful valuation for each disease. Here we report the results of molecular diagnosis of LSDs selected on the basis of disease frequency, possibility of genotype-phenotype correlation studies and carrier identification.

Original languageItalian
Pages (from-to)75-83
Number of pages9
JournalGaslini
Volume33
Issue number1
Publication statusPublished - 2001

Fingerprint

Lysosomal Storage Diseases
Lysergic Acid Diethylamide
Inborn Genetic Diseases
Genetic Association Studies
Mutant Proteins
Prenatal Diagnosis
Cost-Benefit Analysis
Technology
Mutation
Enzymes
Proteins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

La diagnosi molecolare nelle malattie lisosomiali. / Filocamo, M.; Stroppiano, M.; Regis, S.; Mazzotti, R.; Corsolini, F.; Bonuccelli, G.

In: Gaslini, Vol. 33, No. 1, 2001, p. 75-83.

Research output: Contribution to journalArticle

Filocamo, M. ; Stroppiano, M. ; Regis, S. ; Mazzotti, R. ; Corsolini, F. ; Bonuccelli, G. / La diagnosi molecolare nelle malattie lisosomiali. In: Gaslini. 2001 ; Vol. 33, No. 1. pp. 75-83.
@article{6fd07f4ad2654b6f8586c616985b5165,
title = "La diagnosi molecolare nelle malattie lisosomiali",
abstract = "Lysosomal storage disorders (LSD) represent a group of at least 44 distinct genetic disease, each one resulting from a deficiency of a specific enzyme or from protein that are involved in lysosomal biogenesis. Today, with the advent of the new technologies, capabilities to characterise LSDs biochemically and genetically have increased. Contrary to all expectations, the results of the molecular analysis have not always explained the broad clinical heterogeneity of the distinct defects as well as proved very useful to predict the disease severity. However, the molecular analysis makes the diagnosis of carriers and the prenatal tests more reliable. Furthermore, the expression studies of the mutant proteins have improved the knowledge in pathogenesis of the diseases and, sometimes, have provided useful information for therapy establishment. Considering the vast number of mutations for each defect and the accuracy need for the analyses, the cost-benefit analysis requires a careful valuation for each disease. Here we report the results of molecular diagnosis of LSDs selected on the basis of disease frequency, possibility of genotype-phenotype correlation studies and carrier identification.",
keywords = "Lysosomal storage disorders, Molecular analysis",
author = "M. Filocamo and M. Stroppiano and S. Regis and R. Mazzotti and F. Corsolini and G. Bonuccelli",
year = "2001",
language = "Italian",
volume = "33",
pages = "75--83",
journal = "Gaslini",
issn = "0390-5845",
publisher = "Masson SpA",
number = "1",

}

TY - JOUR

T1 - La diagnosi molecolare nelle malattie lisosomiali

AU - Filocamo, M.

AU - Stroppiano, M.

AU - Regis, S.

AU - Mazzotti, R.

AU - Corsolini, F.

AU - Bonuccelli, G.

PY - 2001

Y1 - 2001

N2 - Lysosomal storage disorders (LSD) represent a group of at least 44 distinct genetic disease, each one resulting from a deficiency of a specific enzyme or from protein that are involved in lysosomal biogenesis. Today, with the advent of the new technologies, capabilities to characterise LSDs biochemically and genetically have increased. Contrary to all expectations, the results of the molecular analysis have not always explained the broad clinical heterogeneity of the distinct defects as well as proved very useful to predict the disease severity. However, the molecular analysis makes the diagnosis of carriers and the prenatal tests more reliable. Furthermore, the expression studies of the mutant proteins have improved the knowledge in pathogenesis of the diseases and, sometimes, have provided useful information for therapy establishment. Considering the vast number of mutations for each defect and the accuracy need for the analyses, the cost-benefit analysis requires a careful valuation for each disease. Here we report the results of molecular diagnosis of LSDs selected on the basis of disease frequency, possibility of genotype-phenotype correlation studies and carrier identification.

AB - Lysosomal storage disorders (LSD) represent a group of at least 44 distinct genetic disease, each one resulting from a deficiency of a specific enzyme or from protein that are involved in lysosomal biogenesis. Today, with the advent of the new technologies, capabilities to characterise LSDs biochemically and genetically have increased. Contrary to all expectations, the results of the molecular analysis have not always explained the broad clinical heterogeneity of the distinct defects as well as proved very useful to predict the disease severity. However, the molecular analysis makes the diagnosis of carriers and the prenatal tests more reliable. Furthermore, the expression studies of the mutant proteins have improved the knowledge in pathogenesis of the diseases and, sometimes, have provided useful information for therapy establishment. Considering the vast number of mutations for each defect and the accuracy need for the analyses, the cost-benefit analysis requires a careful valuation for each disease. Here we report the results of molecular diagnosis of LSDs selected on the basis of disease frequency, possibility of genotype-phenotype correlation studies and carrier identification.

KW - Lysosomal storage disorders

KW - Molecular analysis

UR - http://www.scopus.com/inward/record.url?scp=0034974882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034974882&partnerID=8YFLogxK

M3 - Articolo

VL - 33

SP - 75

EP - 83

JO - Gaslini

JF - Gaslini

SN - 0390-5845

IS - 1

ER -